englumafusp alfa (RG6076) / Roche 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
englumafusp alfa (RG6076) / Roche
BP41072, NCT04077723: A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Recruiting
1/2
498
Europe, US, RoW
Englumafusp alfa, A CD19 Targeted 4-1BB Ligand; RO7227166, Obinutuzumab, Gpt, RO5072759, Gazyva, Gazyvaro, Glofitamab, CD20-TCB, RO7082859, Tocilizumab, Actemra, RoActemra
Hoffmann-La Roche
Lymphoma, Non-Hodgkin
03/27
03/27

Download Options